Breaking News, Collaborations & Alliances

ZyVersa, Selexis and KBI Enter Devt. and Mfg. Collaboration

To advance ZyVersa’s lead inflammasome inhibitor into clinic with Selexis and KBI’s integrated development platform

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

JSR Life Sciences Companies Selexis SA and KBI Biopharma have formed a new collaboration with ZyVersa Therapeutics to advance  development of ZyVersa’s lead inflammasome inhibitor, IC 100, for the treatment of multiple inflammatory conditions. Under the collaboration, ZyVersa will leverage Selexis’ cell line expression technologies in combination with KBI Biopharma’s contract development and manufacturing services to advance IC 100 into the clinic. The collaboration includes a commercial license...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters